Fulfilling the Promise of Precision Medicine
ADAPTHERAPY® was founded to improve healthcare for everyone through personalized and precise information. As an innovative biotechnology company ADAPTHERAPY® actively works to fulfill the promise of precision medicine by helping clinicians select the best « Adapted Therapy » for each individual patient with cancer and other complex diseases.
ADAPTHERAPY® is contributing to the new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care.
PREDMED® ADAPTHERAPY®’s first medical solution, is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA). It provides oncologists with the best treatment options among all targeted therapies, including immunotherapy, to personalize cancer care today.
PREDMED® is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA)
PREDMED® is an In-Vitro Theranostic Test in development and can be used for all solid tumor cancers
PREDMED® allows the determination of therapeutically targetable dominant signaling pathways in the cancer sample
PREDMED® predicts the effectiveness of targeted therapies (including immunotherapies) for individual patient treatment.
PREDMED® gives to the clinicians the confidence to select the best individual therapeutic strategy
PREDMED® is the first pharmacogenomic IVDMIA test providing prioritization of the expression of all selected therapeutic targets for a given patient and predicting therapeutic efficacy of targeted cancer therapies, taking into account escape mechanisms.
Diagnostic and prognosis
Prediction of the efficiency of targeted therapies acting on different kind of targets (angiogenesis, migration, repairs, …)
Selection of the best therapeutic strategy for a specific patient, based on targeted therapies (alone or in association)
Stratification of patients in clinical trials and selection of associated targeted therapy to the studied drug
An “All-in-one approach” assessing the expression variation of relevant genes in a single test.
Individualization and optimization of the regimen of each patient.
The signatures, as attested by the validation procedures, are robust in terms of precision, stability and sensitivity.
PREDMED® is an innovative, versatile profiling platform that use validated molecular targets to inform and enhance drug development, advanced diagnostics and prescription of targeted therapies.
Currently being developed for cancer.
ADAPTHERAPY® successfully completed its first funding round
ADAPTHERAPY® has constituted its operational team to validate and to distribute PREDMED®.